Join our daily newsletter At The Bell to receive exclusive market insights
- Total Brain (TTB) has entered a perpetual, non-exclusive licencing deal with Alto Neuroscience
- Under the deal, Total Brain will hand over its International Study to Predict Optimized Treatment for Depression (iSpot-D) research data to Alto
- Total Brain will receive a one-off licence fee of US$500,000 (A$692,266) for handing over its data, with US$100,000 (A$138,453) payable by January 15
- The licence is subject to conventional commercial termination provisions and will come into effect immediately
- Shares in Total Brain are up a healthy 27.3 per cent and are trading at 14 cents
Total Brain (TTB) has entered a perpetual, non-exclusive licencing deal with Alto Neuroscience.
Under the deal, Total Brain will hand over its International Study to Predict Optimized Treatment for Depression (iSpot-D) research data to Alto.
Total Brain will receive a one-off licence fee of US$500,000 (A$692,266) with US$100,000 (A$138,453) payable by January 15 and the remainder within 15 days of the data transfer date of March 31.
Founder and CEO of Alto Amit Etkin said he was pleased to work with Alto.
“Members of the Alto team have a deep knowledge of the iSpot-D study having acquired, worked with and published on its data in the past and have the breadth of expertise necessary to harness its unique value,” Mr Etkin said.
“Alto’s AI-enabled platform and data science team are ideally positioned to extract meaningful insights from the data for our clinical-stage drug development pipeline.”
The licence is subject to conventional commercial termination provisions and will come into effect immediately.
Shares in Total Brain were up a healthy 27.3 per cent on the market and were trading at 14 cents at 1:58 pm AEDT.
